|
1
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Paplomata E and O'Regan R: The
PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and
biomarkers. Ther Adv Med Oncol. 6:154–166. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chakraborty A, Koldobskiy MA, Bello NT,
Maxwell M, Potter JJ, Juluri KR, Maag D, Kim S, Huang AS, Dailey
MJ, et al: Inositol pyrophosphates inhibit akt signaling, thereby
regulating insulin sensitivity and weight gain. Cell. 143:897–910.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Luo HR, Huang YE, Chen JC, Saiardi A,
Iijima M, Ye K, Huang Y, Nagata E, Devreotes P and Snyder SH:
Inositol pyrophosphates mediate chemotaxis in dictyostelium via
pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. Cell.
114:559–572. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Saiardi A, Erdjument-Bromage H, Snowman
AM, Tempst P and Snyder SH: Synthesis of diphosphoinositol
pentakisphosphate by a newly identified family of higher inositol
polyphosphate kinases. Curr Biol. 9:1323–1326. 1999.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A,
Roy B, Roychoudhury S and Panda CK: Alterations of 3p21.31 tumor
suppressor genes in head and neck squamous cell carcinoma:
Correlation with progression and prognosis. Int J Cancer.
123:2594–2604. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ching HC, Naidu R, Seong MK, Har YC and
Taib NA: Integrated analysis of copy number and loss of
heterozygosity in primary breast carcinomas using high-density SNP
array. Int J Oncol. 39:621–633. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274.
2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jadav RS, Kumar D, Buwa N, Ganguli S,
Thampatty SR, Balasubramanian N and Bhandari R: Deletion of
inositol hexakisphosphate kinase 1 (IP6K1) reduces cell migration
and invasion, conferring protection from aerodigestive tract
carcinoma in mice. Cell Signal. 28:1124–1136. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rao F, Cha J, Xu J, Xu R, Vandiver MS,
Tyagi R, Tokhunts R, Koldobskiy MA, Fu C, Barrow R, et al: Inositol
pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by
regulating CK2 phosphorylation of Tti1/Tel2. Mol Cell. 54:119–132.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Koldobskiy MA, Chakraborty A, Werner JK
Jr, Snowman AM, Juluri KR, Vandiver MS, Kim S, Heletz S and Snyder
SH: p53-Mediated apoptosis requires inositol hexakisphosphate
kinase-2. Proc Natl Acad Sci USA. 107:20947–20951. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Morrison BH, Bauer JA, Hu J, Grane RW,
Ozdemir AM, Chawla-Sarkar M, Gong B, Almasan A, Kalvakolanu DV and
Lindner DJ: Inositol hexakisphosphate kinase 2 sensitizes ovarian
carcinoma cells to multiple cancer therapeutics. Oncogene.
21:1882–1889. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Morrison BH, Haney R, Lamarre E, Drazba J,
Prestwich GD and Lindner DJ: Gene deletion of inositol
hexakisphosphate kinase 2 predisposes to aerodigestive tract
carcinoma. Oncogene. 28:2383–2392. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bostner J, Karlsson E, Pandiyan MJ,
Westman H, Skoog L, Fornander T, Nordenskjöld B and Stål O:
Activation of akt, mTOR, and the estrogen receptor as a signature
to predict tamoxifen treatment benefit. Breast Cancer Res Treat.
137:397–406. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Karlsson E, Perez-Tenorio G, Amin R,
Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjöld B, Hallbeck
AL and Stål O: The mTOR effectors 4EBP1 and S6K2 are frequently
coexpressed, and associated with a poor prognosis and endocrine
resistance in breast cancer: A retrospective study including
patients from the randomised stockholm tamoxifen trials. Breast
Cancer Res. 15(R96)2013.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Bostner J, Karlsson E, Eding CB,
Perez-Tenorio G, Franzén H, Konstantinell A, Fornander T,
Nordenskjöld B and Stål O: S6 kinase signaling: Tamoxifen response
and prognostic indication in two breast cancer cohorts. Endocr
Relat Cancer. 22:331–343. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rutqvist LE and Johansson H: Stockhol
Breast Cancer Study Group. Long-Term follow-up of the randomized
stockholm trial on adjuvant tamoxifen among postmenopausal patients
with early stage breast cancer. Acta Oncol. 46:133–145.
2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jerevall PL, Jansson A, Fornander T, Skoog
L, Nordenskjöld B and Stål O: Predictive relevance of HOXB13
protein expression for tamoxifen benefit in breast cancer. Breast
Cancer Res. 12(R53)2010.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Khoshnoud MR, Löfdahl B, Fohlin H,
Fornander T, Stål O, Skoog L, Bergh J and Nordenskjöld B:
Immunohistochemistry compared to cytosol assays for determination
of estrogen receptor and prediction of the long-term effect of
adjuvant tamoxifen. Breast Cancer Res Treat. 126:421–430.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bostner J, Skoog L, Fornander T,
Nordenskjöld B and Stål O: Estrogen receptor-alpha phosphorylation
at serine 305, nuclear p21-activated kinase 1 expression, and
response to tamoxifen in postmenopausal breast cancer. Clin Cancer
Res. 16:1624–1633. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC
Working Group on Cancer Diagnostics. Reporting recommendations for
tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391.
2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009.
2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cancer Genome Atlas Research Network.
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Spratt DE, Chan T, Waldron L, Speers C,
Feng FY, Ogunwobi OO and Osborne JR: Racial/Ethnic disparities in
genomic sequencing. JAMA Oncol. 2:1070–1074. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Esserman LJ, Yau C, Thompson CK, van't
Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B and
Fornander T: Use of molecular tools to identify patients with
indolent breast cancers with ultralow risk over 2 decades. JAMA
Oncol. 3:1503–1510. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Parker JS, Mullins M, Cheang MC, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chakraborty A: The inositol pyrophosphate
pathway in health and diseases. Biol Rev Camb Philos Soc.
93:1203–1227. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Illies C, Gromada J, Fiume R, Leibiger B,
Yu J, Juhl K, Yang SN, Barma DK, Falck JR, Saiardi A, et al:
Requirement of inositol pyrophosphates for full exocytotic capacity
in pancreatic beta cells. Science. 318:1299–1302. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fu C, Xu J, Cheng W, Rojas T, Chin AC,
Snowman AM, Harraz MM and Snyder SH: Neuronal migration is mediated
by inositol hexakisphosphate kinase 1 via α-actinin and focal
adhesion kinase. Proc Natl Acad Sci USA. 114:2036–2041.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gu C, Nguyen HN, Ganini D, Chen Z, Jessen
HJ, Gu Z, Wang H and Shears SB: KO of 5-insP7 kinase activity
transforms the HCT116 colon cancer cell line into a hypermetabolic,
growth-inhibited phenotype. Proc Natl Acad Sci USA.
114:11968–11973. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Al Sarakbi W, Sasi W, Jiang WG, Roberts T,
Newbold RF and Mokbel K: The mRNA expression of SETD2 in human
breast cancer: Correlation with clinico-pathological parameters.
BMC Cancer. 9(290)2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Roberti A, Dobay MP, Bisig B, Vallois D,
Boéchat C, Lanitis E, Bouchindhomme B, Parrens MC, Bossard C and
Quintanilla-Martinez L: Type II enteropathy-associated T-cell
lymphoma features a unique genomic profile with highly recurrent
SETD2 alterations. Nat Commun. 7(12602)2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Duns G, van den Berg E, van Duivenbode I,
Osinga J, Hollema H, Hofstra RM and Kok K: Histone
methyltransferase gene SETD2 is a novel tumor suppressor gene in
clear cell renal cell carcinoma. Cancer Res. 70:4287–4291.
2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang S, Fan G, Hao Y, Hammell M,
Wilkinson JE and Tonks NK: Suppression of protein tyrosine
phosphatase N23 predisposes to breast tumorigenesis via activation
of FYN kinase. Genes Dev. 31:1939–1957. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sadeghi H, Golalipour M, Yamchi A,
Farazmandfar T and Shahbazi M: CDC25A pathway toward tumorigenesis:
Molecular targets of CDC25A in cell-cycle regulation. J Cell
Biochem. 120:2919–2928. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Malik MF, Ye L and Jiang WG: Reduced
expression of semaphorin 4D and plexin-B in breast cancer is
associated with poorer prognosis and the potential linkage with
oestrogen receptor. Oncol Rep. 34:1049–1057. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang C, Wang HJ, Bao QC, Wang L, Guo TK,
Chen WL, Xu LL, Zhou HS, Bian JL, Yang YR, et al: NRF2 promotes
breast cancer cell proliferation and metastasis by increasing
RhoA/ROCK pathway signal transduction. Oncotarget. 7:73593–73606.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jeong D, Park S, Kim H, Kim CJ, Ahn TS,
Bae SB, Kim HJ, Kim TH, Im J, Lee MS, et al: RhoA is associated
with invasion and poor prognosis in colorectal cancer. Int J Oncol.
48:714–722. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Agathanggelou A, Cooper WN and Latif F:
Role of the ras-association domain family 1 tumor suppressor gene
in human cancers. Cancer Res. 65:3497–3508. 2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Blanchard TG, Lapidus R, Banerjee V,
Bafford AC, Czinn SJ, Ahmed H and Banerjee A: Upregulation of
RASSF1A in colon cancer by suppression of angiogenesis signaling
and akt activation. Cell Physiol Biochem. 48:1259–1273.
2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chakraborty A, Koldobskiy MA, Sixt KM,
Juluri KR, Mustafa AK, Snowman AM, van Rossum DB, Patterson RL and
Snyder SH: HSP90 regulates cell survival via inositol
hexakisphosphate kinase-2. Proc Natl Acad Sci USA. 105:1134–1139.
2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Nagata E, Saiardi A, Tsukamoto H, Okada Y,
Itoh Y, Satoh T, Itoh J, Margolis RL, Takizawa S, Sawa A and Takagi
S: Inositol hexakisphosphate kinases induce cell death in
huntington disease. J Biol Chem. 286:26680–26686. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nagata E, Nonaka T, Moriya Y, Fujii N,
Okada Y, Tsukamoto H, Itoh J, Okada C, Satoh T, Arai T, et al:
Inositol hexakisphosphate kinase 2 promotes cell death in cells
with cytoplasmic TDP-43 aggregation. Mol Neurobiol. 53:5377–5383.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Moriya Y, Nagata E, Fujii N, Satoh T,
Ogawa H, Hadano S and Takizawa S: Inositol hexakisphosphate kinase
2 is a presymptomatic biomarker for amyotrophic lateral sclerosis.
Tokai J Exp Clin Med. 42:13–18. 2017.PubMed/NCBI
|
|
46
|
Rao F, Xu J, Fu C, Cha JY, Gadalla MM, Xu
R, Barrow JC and Snyder SH: Inositol pyrophosphates promote tumor
growth and metastasis by antagonizing liver kinase B1. Proc Natl
Acad Sci USA. 112:1773–1778. 2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Izaguirre G, Aguirre L, Hu YP, Lee HY,
Schlaepfer DD, Aneskievich BJ and Haimovich B: The
cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated
on its actin-binding domain by the focal adhesion kinase. J Biol
Chem. 276:28676–28685. 2001.PubMed/NCBI View Article : Google Scholar
|
